ABSTRACT
The objective of this study was validation of a reverse phase HPLC method for the estimation of metoclopramide HCl in plasma already validated for determination of metoclopramide HCl in tablets dosage form. A reverse chromatographic method was used for estimation of metoclopramide HCl with the mobile phase of acetonitrile, 20mM potassium dihydrogen phosphate buffer solution [pH 3.0 adjusted with orthophosphoric acid] in the ratio of 40: 60. The column used was Waters C18 3.9x300mm micro Bondapak [RP]. The flow rate of the mobile phase was 2ml/ minute. The detector was set at the wavelength of 275nm. This method validated in plasma and was found to be linear, with correlation coefficient [R[2]], value of 0.9988, in the range of 48 ng/ml-0.25ng/ml. The method modified was accurate, precise, sensitive and showed good stability results. The % RSD of the retention time and peak area of metoclopramide HCl was 0.19% and 1.44% respectively. All the parameters such as specificity, linearity, range, accuracy, precision, system suitability, solution stability, detection and quantification limits were evaluated to validate this method and were found within the acceptance limits. The method can be effectively used for estimation of metoclopramide HCl in plasma
Subject(s)
Humans , Calibration , Metoclopramide/blood , Metoclopramide/pharmacokinetics , Reproducibility of Results , Drug StabilityABSTRACT
This study was conduced in normotensive and hypertensive patients at the Vargas Hospital of Caracas. Normotensive subjects received, in a crossover fashion, placebo, metoclopramide or domperidone, 40 mg of each drug daily for one week. The first group of patients under placebo for one(1) week received a single 2.5 mg oral dose bromocriptine (Br). The second group of patients received 30 mg of metoclopramide (MTC) daily (divided in 3 doses) for week. At the end of period a single dose of 2.5 mg of Br was given to each patient . The third group received domperidone (DOMP) during one week at 30 mg/daily dose to eight hypertesive patients and then a single dose of 2.5 mg Br. Cardiovascular and biochemical parameters including arterial pressure, heart rate, plasma renin activity, and plasma aldosterone concentration were evaluated during the 6 hour period before and after the administration of Br. Neither DOMP nor MTC modified significantly blood presure and heart rate in normotensive subjects. Br reduced both systolic and diastolic arterial pressure in hypertensive subjects. The peak of antihypertensive effect appeared 3 hours after drug administration, but reduction of arterial pressure lasted aproximately 6 hours. At the same time Br reduced plasma aldosterone levels and plasma renin activity. MTC and DOMP reversed the antihypertensive effct or Br and its effect on aldosterone levels and plasma renin activity. We conclude from these findings that Br acts as an antihypertensive agent at peripheral and central levels by stimulating DA2 receptors, which are involved in the aldosterone and renin secretion
Subject(s)
Humans , Male , Female , Bromocriptine , Domperidone , Domperidone/blood , Hypertension/therapy , Metoclopramide , Metoclopramide/blood , PatientsABSTRACT
Twenty two (22) hypertensive patients were studied during handgrip test before and during metoclopramide treatment. Metoclopamide was intravenously administered at the rate of 7,5 µg/kg/min during a period of 30 min. Two placebo periods before and after metoclopramide infusion were employed. There was an increase of blood pressure and heart rate during handrgrid test; however, metaclopramide decreased blood pressure prior to handgrip test. In labetalol pretreated hypertensive patients (600-800 mg/daily po, during 7 days period), metoclopramide decreased greater blood pressure before and after handgrip test. Postmenopausal women reacted greater that premenopausal women. It appers that premenopausal women exhibit a vasculoprotecting effect during handgrip which should be attributed to estrogen secretion